MRK · 8-K · 20261029PR119825

Acquisitions and Divestitures

Merck & Co., Inc. · 2026-10-29 · Importance 71 · Surprise 60

The 2026 outlook includes one-time R&D charges of $9.0 billion related to the acquisition of Cidara Therapeutics and $5.7 billion related to the acquisition of Terns Pharmaceuticals. Those charges equate to $3.62 and $2.31 per share, respectively, in the non-GAAP EPS outlook. The company’s outlook does not assume additional significant potential business development transactions.

Key facts

• Merck acquired Verona Pharma plc in October 2025, and OHTUVAYRE sales were obtained as part of that acquisition. source